• Lung surfactants/mucolytics

Survanta Generic Name & Formulations

General Description

Beractant (as phospholipids) 25mg/mL; susp for intratracheal administration; preservative-free.

Pharmacological Class

Lung surfactant.

How Supplied

Vials (4mL, 8mL)—1


Survanta Indications


Prevention and treatment of respiratory distress syndrome (RDS) in premature infants.

Survanta Dosage and Administration


See literature for dosing chart, administration, and additional support procedures. 100mg of phospholipids (4mL)/kg birth weight per dose, by intratracheal administration; max 4 doses, at 6-hr intervals in the first 48hrs after birth. Rescue: give 1st dose as soon as possible after infant is placed on mechanical ventilation for treatment of RDS. Prevention: give 1st dose as soon as possible after birth, preferably within 15 mins. Avoid suctioning for 1 hour after treatment, unless significant airway obstruction occurs. Retreatment is determined by continued respiratory distress. Get radiographic confirmation of RDS in those infants given preventative dose before giving additional doses.

Survanta Contraindications

Not Applicable

Survanta Boxed Warnings

Not Applicable

Survanta Warnings/Precautions


Interrupt dosing if bradycardia or oxygen desaturation occurs; treat; resume after stabilization. Monitor oxygenation, carbon dioxide, and clinical condition frequently and carefully.

Survanta Pharmacokinetics

See Literature

Survanta Interactions

Not Applicable

Survanta Adverse Reactions

Adverse Reactions

Dosing procedure reactions including oxygen desaturation and bradycardia, rales, moist breath sounds, sepsis, intracranial hemorrhage.

Survanta Clinical Trials

See Literature

Survanta Note

Not Applicable

Survanta Patient Counseling

See Literature